Article Test

Home  >  Medical Research Archives  >  Issue 149  > Phloridzin docosahexaenoate, a novel polyphenolic derivative, is cytotoxic to canine osteosarcoma D17 cells
Published in the Medical Research Archives
May 2021 Issue

Phloridzin docosahexaenoate, a novel polyphenolic derivative, is cytotoxic to canine osteosarcoma D17 cells

Published on May 25, 2021

DOI 

Abstract

 

Canine osteosarcoma (OSA) is the most common form of bone cancer diagnosticated in dogs and is highly metastatic. There has been limited advancement in discovering an effective treatment for OSA in the last few decades. The major drawback of the currently used chemotherapeutic drugs is their side effects. In this preliminary study, we investigated the efficacy of using a novel food-derived drug, phloridzin docosahexaenoate (PZ-DHA), in the treatment of canine OSA in vitro. PZ-DHA was selectively cytotoxic to canine OSA D17 cells, while normal human liver cells (WRL68) were more resistant. We also found that PZ-DHA had enhanced cellular uptake in D17 cells compared to its precursors and in WRL68 cell line. This study provides preliminary evidence that PZ-DHA needs to be further assessed as a safe and efficacious new drug in the treatment of both canine and human OSA.

Author info

H.p. Vasantha Rupasinghe, Niroshaa Arumuggam, Beth Murray, Tess Astatkie

Have an article to submit?

Submission Guidelines

Submit a manuscript

Become a member

Call for papers

Have a manuscript to publish in the society's journal?